智通财经记者 | 黄华 智通财经编辑 | 谢欣 2月24日，前沿生物公告称，与跨国药企葛兰素史克（GSK）达成独家授权许可协议，授予其两款小核 酸（siRNA） 管线产品在全球范围内的独家开发、生产及商业化权利，其中一款候选药物已进入新药 临床试验申请（IND）阶段，另一款尚在临床前阶段。 根据协议，前沿生物将获得4000万美元首付款及1300万美元近期里程碑付款，还将额外在两个项目中累 计获得最高9.5亿美元的里程碑付款。 前沿生物将负责两款在研产品的早期开发工作，包括其中一款产品在中国的I期临床试验推进，以及另 一款产品的临床试验申请支持性研究；葛兰素史克将负责两款产品之后所有的全球临床开发、监管申报 及商业化活动。 此番分工可能也意味着，若是授权产品未能达到前述预期阶段，葛兰素史克也不会推进后续开发。 前沿生物提出，与葛兰素史克达成此授权合作，将为公司带来首付款及后续里程碑付款，有助于改善现 金流，但合作后续进展与最终能实际收获的授权金额存在不确定性。 沿生物业绩情况 制图：智通财经记者 黄华 2月24日，前沿生物涨停开盘，开盘报27.12元/股，但随后股价下跌。截至2月24日收盘，该公司报收 24.7 ...

Investment Rating - The report indicates a positive investment outlook for the IgA nephropathy drug market, transitioning from "no drugs available" to "multiple drugs available" [2]. Core Insights - IgA nephropathy (IgAN) is one of the most common primary glomerulonephritis globally and particularly prevalent in China, with a national prevalence rate of 39.73% among primary glomerulonephritis patients [25]. - The global drug development landscape for IgAN is concentrated in late-stage clinical trials, with significant interest from multinational pharmaceutical companies in the Chinese market [36]. - There are currently 6 approved drugs, 1 NDA drug, 10 drugs in Phase III trials, 19 in Phase II, 11 in Phase I, and 8 in IND status globally [6]. Summary by Sections Part 1: Overview of IgA Nephropathy - IgA nephropathy is characterized by the deposition of IgA in the mesangial area of the glomeruli, leading to inflammation and potential kidney damage [10][12]. - The disease's pathogenesis is based on the "four-hit hypothesis," which outlines a sequence of events leading to clinically significant disease [20]. - The average age of diagnosis for IgAN patients in China is around 34 years, with a male-to-female ratio of approximately 58.67% to 41.33% [25]. Part 2: Drug Development for IgA Nephropathy - The report highlights a robust pipeline for IgA nephropathy treatments, with a focus on targeting the first and fourth hits in the disease mechanism [36][37]. - Notable drugs in development include Budesonide, which targets abnormal IgA1 glycosylation, and various monoclonal antibodies aimed at different pathways involved in IgAN [40][43]. - The Chinese drug development landscape mirrors global trends, with a significant number of products expected to enter the market in the coming years [36]. Part 3: Market Situation of Approved IgA Nephropathy Drugs - The market for IgA nephropathy drugs has rapidly expanded, with many products launched in recent years, indicating a shift towards a competitive landscape [73]. - The report emphasizes the importance of the Chinese market, where drugs like Acetylcysteine and Budesonide have seen swift approvals following their global launches [36]. - The competitive dynamics are expected to intensify as more treatments become available, transitioning the market from limited options to a variety of therapeutic choices [36].

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [2] Core Views - The pharmaceutical and biotechnology industry index experienced a decline of 4.40%, ranking 23rd among 31 primary industries, underperforming the CSI 300 index which fell by 2.19% [6][18] - The valuation of the pharmaceutical and biotechnology industry as of November 28, 2025, is a PE (TTM overall method, excluding negative values) of 29.46x, down from 30.89x in the previous period, indicating a downward trend and below the average [22] - The report highlights potential beneficiaries from the upcoming ASH data, particularly in blood diseases and companies with solid grassroots channels, as well as those with differentiated advantages in oncology, autoimmune, and rare disease products [10] Summary by Sections Industry Review - The pharmaceutical and biotechnology industry index fell by 4.40%, with chemical preparations and medical devices showing declines of 2.86% and 2.95% respectively, while offline pharmacies and vaccines saw larger declines of 8.22% and 6.42% [6][18] - The PE ratio for the pharmaceutical and biotechnology industry is 29.46x, with the highest valuations in the vaccine (47.56x), hospital (41.17x), and medical device (36.77x) sectors, while pharmaceutical circulation has the lowest at 14.58x [22] Important Industry News - The National Administration of Traditional Chinese Medicine and the National Healthcare Security Administration released a directory for traditional Chinese medicine diseases suitable for disease-based payment [26][27] - AstraZeneca's drug "Durvalumab" received FDA approval for a new indication in perioperative treatment of gastric cancer [32] - Otsuka Pharmaceutical's new drug for IgA nephropathy, "Sibeprenlimab," has been approved by the FDA [38] - Bayer's first-in-class lung cancer drug "Sevabertinib" has been approved by the FDA for specific patient populations [40] Investment Recommendations - Focus on innovative pharmaceutical companies that may benefit from the medical insurance or commercial insurance directories, blood cancer targets with imminent ASH data releases, and biotech and CXO leaders with solid technology platforms and international collaboration expectations [10]

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating an "Overweight" rating, suggesting that the industry is expected to outperform the overall market [28]. Core Insights - The report highlights a 2.7% increase in the Shenwan Pharmaceutical and Biological Index, outperforming the Shanghai Composite Index, which rose by 1.4% [3][5]. - The report emphasizes the importance of monitoring changes in flu epidemics and their impact on the pharmaceutical sector, particularly regarding vaccine and treatment demand [2]. - Key domestic developments include the approval of new indications for innovative drugs and significant stock purchases by company executives, indicating confidence in the sector [12][13]. Market Performance - The Shenwan Pharmaceutical and Biological Index rose by 2.7% this week, ranking 17th among 31 Shenwan first-level sub-industries [3][5]. - The overall valuation of the pharmaceutical sector stands at 29.5 times earnings, placing it 10th among 31 Shenwan first-level industries [5][10]. Recent Key Events Domestic Developments - The State Council meeting discussed enhancing the basic medical insurance system, which is expected to improve the efficiency of fund management and healthcare resource allocation [11]. - Major companies like Mindray Medical and Huyuan Bio are making significant moves, such as stock buybacks and new product approvals, which are seen as positive indicators for the industry [12][13]. International Developments - The report notes the approval of groundbreaking drugs, including the first siRNA drug for treating familial chylomicronemia syndrome, and highlights the challenges faced by other drugs in clinical trials [15][16][17]. Investment Recommendations - The report suggests focusing on innovative drug sectors and companies with strong performance metrics, including Heng Rui Pharmaceutical, Changchun High-tech, and Mindray Medical, among others [2][12]. - It also recommends monitoring companies involved in flu vaccines and treatments as flu activity increases [2].

Investment Rating - The report maintains an investment rating of "Outperform" [6] Core Insights - The report highlights that Weili Zhibo is set to officially list on the Hong Kong Stock Exchange on July 25, 2025, with a pipeline of approximately 14 candidate drugs, 6 of which are in clinical development. The core product, the second-generation IO product PD-L1/4-1BB bispecific antibody LBL-024, is currently in a key registration clinical phase for treating lung neuroendocrine tumors [2][18] - The report notes that several PD-L1/4-1BB bispecific antibodies are under development globally, with Genmab's Acasunlimab leading in progress, having initiated a Phase III clinical trial for PD-L1 positive NSCLC in the second line. Weili Zhibo's LBL-024 is also in a critical registration clinical study for lung neuroendocrine tumors [21][22] - Early data from the PD-L1/4-1BB bispecific antibodies indicate that Weili Zhibo's LBL-024 has shown excellent overall response rate (ORR) data in first-line SCLC treatment, while Genmab's Acasunlimab has demonstrated superior survival data in second-line PD-L1 positive NSCLC [26] Summary by Sections Weekly New Drug Market Review - From July 14 to July 20, 2025, the top five companies in the new drug sector by stock price increase were Lepu Biotech (62.0%), Deqi Pharma (47.04%), Kaituo Pharma (41.99%), JAKS (41.95%), and Gilead Sciences (31.15%) [14][16] Weekly New Drug Industry Key Analysis - Weili Zhibo's innovative drug pipeline includes 14 candidate drugs, with 6 in clinical development. The focus is on the PD-L1/4-1BB bispecific antibody LBL-024, which is in a key registration clinical phase for lung neuroendocrine tumors [2][18] Weekly New Drug Approval & Acceptance Status - No new drug or new indication approvals were granted this week, but 6 new drug applications were accepted [3] Weekly New Drug Clinical Application Approval & Acceptance Status - This week, 35 new drug clinical applications were approved, and 28 new drug clinical applications were accepted [4] Domestic Market Key Events TOP3 - Baiyue Shenzhou's application for the injection of Talazotuzumab for treating extensive-stage small cell lung cancer (ES-SCLC) has been accepted [5] Overseas Market Key Events TOP3 - Otsuka Pharmaceutical's APRIL antibody is expected to be included in priority review for treating adult primary immunoglobulin A nephropathy [10]